ArticleThe Journal of experimental medicine2020
Adoptive cell therapy: Living drugs against cancer.
Article in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions.Acta pharmacologica Sinica · 2026Review
- Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives.Vaccines · 2026Review
- Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Advances in nucleic acid-based cancer vaccines.Journal of biomedical science · 2025Review
- Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.Frontiers in oncology · 2025Review
- Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.World journal of clinical cases · 2024Article
- Immunologic and Targeted Molecular Therapies for Chordomas: A Narrative Review.Journal of clinical medicine · 2024Review
- AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells.Nature biomedical engineering · 2024Article
- Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.Cell adhesion & migration · 2023Review
- Evolving therapeutic landscape of advanced hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2023Review
- Immunotherapy for hepatocellular carcinoma: Current status and future perspectives.World journal of gastroenterology · 2023Review
- The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.Frontiers in immunology · 2023Review
- The impact of microbially modified metabolites associated with obesity and bariatric surgery on antitumor immunity.Frontiers in immunology · 2023Review
- CRISPR/Cas9-induced structural variations expand in T lymphocytes in vivo.Nucleic acids research · 2022Article
- Gene and cell therapies in China: booming landscape under dual-track regulation.Journal of hematology & oncology · 2022Article
- Review
- Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies.Frontiers in oncology · 2022Article
- Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer.Cancers · 2021Review
- Ex Vivo High Salt Activated Tumor-Primed CD4+T Lymphocytes Exert a Potent Anti-Cancer Response.Cancers · 2021Article
- Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immunotherapy has made a profound impact in the treatment of cancer in the last decade. Insights from the study of the intricate relationships between immune cells and cancer have led to the clinical development of strategies that redirect the power of the immune system to target and eliminate cancer. Today, immunotherapy represents a rapidly expanding and transformative force comprising multiple modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.